Published in J Cell Biochem on August 01, 2010
Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-κB, AP-1 and NF-AT. PLoS One (2012) 1.07
Leishmanicidal activity of two naphthoquinones against Leishmania donovani. Biol Pharm Bull (2012) 1.02
Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther (2011) 0.97
Natural compounds as modulators of NADPH oxidases. Oxid Med Cell Longev (2013) 0.94
T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules. Cytokine (2011) 0.92
The natural anticancer agent plumbagin induces potent cytotoxicity in MCF-7 human breast cancer cells by inhibiting a PI-5 kinase for ROS generation. PLoS One (2012) 0.92
Plumbagin, a vitamin K3 analogue, abrogates lipopolysaccharide-induced oxidative stress, inflammation and endotoxic shock via NF-κB suppression. Inflammation (2014) 0.83
Plumbagin reduces human colon cancer cell survival by inducing cell cycle arrest and mitochondria-mediated apoptosis. Int J Oncol (2014) 0.78
Naphthoquinone-mediated inhibition of lysine acetyltransferase KAT3B/p300, basis for non-toxic inhibitor synthesis. J Biol Chem (2014) 0.78
Antiproliferative effects of Plumbago rosea and its purified constituent plumbagin on SK-MEL 28 melanoma cell lines. Pharmacognosy Res (2014) 0.77
Plumbagin Protects Mice from Lethal Sepsis by Modulating Immunometabolism Upstream of PKM2. Mol Med (2016) 0.77
Healthy ageing and depletion of intracellular glutathione influences T cell membrane thioredoxin-1 levels and cytokine secretion. Chem Cent J (2013) 0.77
Lead Phytochemicals for Anticancer Drug Development. Front Plant Sci (2016) 0.75
A highly sensitive and genetically encoded fluorescent reporter for ratiometric monitoring of quinones in living cells. Chem Commun (Camb) (2013) 0.75
Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol (2003) 6.91
Thiol chemistry and specificity in redox signaling. Free Radic Biol Med (2008) 3.68
Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem Sci (2009) 2.87
Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci U S A (2006) 2.51
Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U S A (2002) 2.35
Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem Pharmacol (2005) 2.28
Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal (2005) 1.81
Identification of oxidant-sensitive proteins: TNF-alpha induces protein glutathiolation. Biochemistry (2000) 1.70
Thiol oxidation in signaling and response to stress: detection and quantification of physiological and pathophysiological thiol modifications. Free Radic Biol Med (2007) 1.63
Cytotoxic action of juglone and plumbagin: a mechanistic study using HaCaT keratinocytes. Chem Res Toxicol (2004) 1.48
Concern Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood (2008) 1.42
Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J Neurochem (2009) 1.39
Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry (1994) 1.38
T cell apoptosis and reactive oxygen species. J Clin Invest (2003) 1.35
Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res (2004) 1.28
Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol (2003) 1.26
Control of Bcl-2 expression by reactive oxygen species. Proc Natl Acad Sci U S A (2003) 1.26
Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes. Int Immunopharmacol (2009) 1.24
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia (2009) 1.22
Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid Redox Signal (2009) 1.21
Antioxidant properties of Plumbago zeylanica, an Indian medicinal plant and its active ingredient, plumbagin. Redox Rep (2004) 1.20
Chemical depletion of glutathione in vivo. Methods Enzymol (1981) 1.20
Plumbagin: A study of its anticancer, antibacterial & antifungal properties. Indian J Exp Biol (1980) 1.18
Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog (2004) 1.12
Longitudinal exposure of human T lymphocytes to weak oxidative stress suppresses transmembrane and nuclear signal transduction. J Immunol (1994) 1.08
Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol (2007) 1.02
Glutathionylation regulates IkappaB. Biochem Biophys Res Commun (2008) 0.94
Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol (2001) 0.94
Oxidative stress suppresses transcription factor activities in stimulated lymphocytes. Clin Exp Immunol (1998) 0.93
Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinoma in vivo and Leishmania donovani Promastigotes in vitro. Phytother Res (2002) 0.90
Molecular events in the activation of B cells and macrophages by a non-microbial TLR4 agonist, G1-4A from Tinospora cordifolia. Immunol Lett (2009) 0.90
Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells. Int Immunol (1997) 0.89
Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Indian J Physiol Pharmacol (1997) 0.89
Immunomodulatory and radioprotective effects of lignans derived from fresh nutmeg mace (Myristica fragrans) in mammalian splenocytes. Int Immunopharmacol (2008) 0.87
Differential mechanisms of cell killing by redox cycling and arylating quinones. Arch Toxicol (1996) 0.86
Thimerosal induces TH2 responses via influencing cytokine secretion by human dendritic cells. J Leukoc Biol (2006) 0.86
Pre-exposure to oxidative stress decreases the nuclear factor-kappa B-dependent transcription in T lymphocytes. J Immunol (1998) 0.85
Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol (1996) 0.85
Effect of in vitro generation of oxygen free radicals on T cell function in young and old rats. Free Radic Biol Med (1998) 0.84
Antiapoptotic and immunomodulatory effects of chlorophyllin. Mol Immunol (2006) 0.82
Molecular mechanisms mediating oxidative stress-induced T-cell suppression in cancer. Adv Enzyme Regul (2008) 0.81
Differential modulation of mitogen driven proliferation and homeostasis driven proliferation of T cells by rapamycin, Ly294002 and chlorophyllin. Mol Immunol (2007) 0.80
Antioxidant defense system in differentially hydrogen peroxide sensitive L5178Y sublines. Free Radic Biol Med (1997) 0.79
Spatial distribution, kinetics, signaling and cytokine production during homeostasis driven proliferation of CD4+ T cells. Mol Immunol (2009) 0.77
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 2.29
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer (2007) 1.86
Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. FEMS Microbiol Lett (2004) 1.86
Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol (2008) 1.77
Preliminary report on cardiac dysfunction after isolated traumatic brain injury. Crit Care Med (2014) 1.65
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol (2009) 1.61
A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2010) 1.58
Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res (2008) 1.57
Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res (2008) 1.55
A semantic-web oriented representation of the clinical element model for secondary use of electronic health records data. J Am Med Inform Assoc (2012) 1.51
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2008) 1.50
Atrial fibrillation: recent advances in understanding the role of microRNAs in atrial remodeling with an electrophysiological overview. Cardiology (2015) 1.48
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res (2008) 1.45
Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol (2008) 1.43
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 1.43
Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med (2010) 1.43
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.43
The formation of straight and twisted filaments from short tau peptides. J Biol Chem (2004) 1.43
Concern Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood (2008) 1.42
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer (2010) 1.42
Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. Med Phys (2010) 1.41
Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol (2007) 1.39
Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem (2007) 1.34
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer (2009) 1.32
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun (2012) 1.31
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) (2010) 1.30
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol (2006) 1.29
Vasopressor use and effect on blood pressure after severe adult traumatic brain injury. Neurocrit Care (2011) 1.29
ST elevation--an indication of reversible neurogenic myocardial dysfunction in patients with head injury. Ann Card Anaesth (2009) 1.28
Transcription and autoregulation of the Rv3134c-devR-devS operon of Mycobacterium tuberculosis. Microbiology (2005) 1.27
Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT. Int J Radiat Oncol Biol Phys (2007) 1.27
Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys (2009) 1.26
Mycobacterium smegmatis and tuberculosis. Trends Microbiol (2002) 1.25
Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes. Int Immunopharmacol (2009) 1.24
Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol (2010) 1.24
Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci (2009) 1.23
Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys (2007) 1.23
Cerebral hemodynamic predictors of poor 6-month Glasgow Outcome Score in severe pediatric traumatic brain injury. J Neurotrauma (2009) 1.22
Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol (2010) 1.22
Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol (2011) 1.20
Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol (2009) 1.19
{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res (2010) 1.17
Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J Virol (2005) 1.16
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys (2006) 1.16
Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem (2007) 1.14
A functional single-molecule binding assay via force spectroscopy. Proc Natl Acad Sci U S A (2007) 1.14
Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol (2008) 1.13
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys (2009) 1.10
Comprehensive insights into Mycobacterium tuberculosis DevR (DosR) regulon activation switch. Nucleic Acids Res (2011) 1.10
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol (2008) 1.09
Structure of core domain of fibril-forming PHF/Tau fragments. Biophys J (2005) 1.09
Filaments of the Ure2p prion protein have a cross-beta core structure. J Struct Biol (2005) 1.09
4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol (2008) 1.08
Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs (2007) 1.08
Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-κB, AP-1 and NF-AT. PLoS One (2012) 1.07
Synthesis, Biological, Spectral, and Thermal Investigations of Cobalt(II) and Nickel(II) Complexes of N-Isonicotinamido -2',4'-Dichlorobenzalaldimine. Bioinorg Chem Appl (2006) 1.06
Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein. J Biol Chem (2003) 1.06
Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 1.06
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res (2012) 1.05
JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J Mol Neurosci (2010) 1.05
Purification and characterization of a protein-phosphotyrosine phosphatase from rat spleen which dephosphorylates and inactivates a tyrosine-specific protein kinase. J Biol Chem (1989) 1.05
The non-protein coding breast cancer susceptibility locus Mcs5a acts in a non-mammary cell-autonomous fashion through the immune system and modulates T-cell homeostasis and functions. Breast Cancer Res (2011) 1.05
Curcumin protects against electrobehavioral progression of seizures in the iron-induced experimental model of epileptogenesis. Epilepsy Behav (2008) 1.05
Modification of immune response by low dose ionizing radiation: role of apoptosis. Immunol Lett (1999) 1.05
Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol (2008) 1.04
Nanoparticle-mediated hyperthermia in cancer therapy. Ther Deliv (2011) 1.04
Immune system and antioxidants, especially those derived from Indian medicinal plants. Indian J Exp Biol (2002) 1.03
Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-κB. Free Radic Biol Med (2012) 1.02
A metabolic and functional overview of brain aging linked to neurological disorders. Biogerontology (2009) 1.02
Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions. Biogerontology (2006) 1.02
Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer (2011) 1.02
A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer (2012) 1.00
Nanoscale organic and polymeric field-effect transistors as chemical sensors. Anal Bioanal Chem (2005) 1.00
Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem (2006) 1.00
Influence of Hsp70s and their regulators on yeast prion propagation. Prion (2009) 0.99
Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol (2010) 0.99
Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim (2008) 0.98
Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain. Neurotoxicology (2006) 0.98
Metformin use and improved response to therapy in rectal cancer. Cancer Med (2013) 0.97
Prodigiosins as anti cancer agents: living upto their name. Curr Pharm Des (2009) 0.97
Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 0.97
Classification of protein aggregates. J Pharm Sci (2011) 0.97
Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy. Phys Med Biol (2010) 0.97
Cell electrophoretic studies on mouse lymphocytes treated with concanavalin A: possible existence of two types of receptors on cell surface. Immunology (1979) 0.96
Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. J Ethnopharmacol (2006) 0.95